Suppr超能文献

在烷化剂抗性亚系融合后分离得到的L1210白血病杂种细胞。

L1210 leukemia hybrids isolated after fusion of alkylating agent-resistant sublines.

作者信息

Schmid F A, Otter G M, Hirano I

机构信息

Laboratory of Experimental Antitumor Testing, Memorial Sloan-Kettering Cancer Center, New York 10021.

出版信息

Leuk Res. 1988;12(1):67-70. doi: 10.1016/s0145-2126(98)80010-6.

Abstract

The two resistant lines, L1210/CPA (cyclophosphamide) and L1210/MeCCNU (1-(2-chloroethyl)-3-(trans-4-methyl-cyclohexyl)-1-nitrosourea) were used, each of which is not cross-resistant to the drug to which the other line is resistant. Their resistance was used as markers as well as the basis for selection of the hybrids. For the production of hybrids five in-vivo or in-vitro schedules were employed. The in-vitro methods produced six successful hybrid lines, but the in-vivo schedules produced none. Resistance to both CPA and MeCCNU was expressed dominantly in the hybrids. The hybrids had chromosome modes ranging from 68 to 78. This study shows that CPA and MeCCNU can be used both as markers and as selective agents, and that CPA and MeCCNU resistance in L1210 leukemia are dominantly expressed in the hybrid.

摘要

使用了两条耐药细胞系,L1210/CPA(环磷酰胺)和L1210/MeCCNU(1-(2-氯乙基)-3-(反式-4-甲基环己基)-1-亚硝基脲),其中每条细胞系对另一条细胞系所耐药的药物不存在交叉耐药性。它们的耐药性既作为标记物,也作为杂种细胞选择的基础。为了产生杂种细胞,采用了五种体内或体外方案。体外方法产生了六个成功的杂种细胞系,但体内方案未产生杂种细胞系。对CPA和MeCCNU的耐药性在杂种细胞中呈显性表达。杂种细胞的染色体模式范围为68至78。本研究表明,CPA和MeCCNU既可用作标记物,也可用作选择剂,并且L1210白血病中对CPA和MeCCNU的耐药性在杂种细胞中呈显性表达。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验